Until Now...
-
The predominant approach in oncology drug discovery and development has been to oversimplify cancer cell biology by focusing on singular molecular targets.
​
-
The drugs targeting isolated pieces of cancer cell biology commonly fail in the clinic because they do not address cancer cell heterogeneity.
​
-
The rationale and design of historical combination therapies is predicated on combining anticancer drugs at their maximal tolerated doses with little emphasis on scientific rationale,
i.e. random additions of drug A and drug B.
​​
-
These historical approaches typically produce excessive toxicity and fail to advance
​the standard of care.
​
-
A paradigm shift is desperately needed to transform how we design combinatorial therapies....
The Nouveau Difference
​
-
Nouveau deploys a proprietary platform technology to accelerate the discovery and synthesis of limitless new oncology drugs.
​​
-
Our technology coupled with our pioneering expertise in nanochemistry can produce new derisked drug entities that leverage scientific rationale to generate drug candidates with superior safety, efficacy and pharmacologic features.
​
-
The platform allows our new drug entities to be bioconjugated, enhancing honing of the therapeutic entity to the tumor and tumor microenvironment.